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1. Introduction
It is becoming clear that a history of traumatic brain injury predisposes individuals to neuro‐
degeneration later in life. Even mild recurrent brain concussions, often neglected, can have
serious consequences. For example, people engaged in contact-sports such as American
football, ice hockey or boxing, and also military personnel, suffer from recurrent brain
concussions with no loss of consciousness and no need for hospitalization. However, these
people face the possibility of long-term neurocognitive problems with increased risk of
developing dementia, including Alzheimer’s disease, Parkinson’s disease and amyotrophic
lateral sclerosis [1-7]. The mechanisms responsible for the post-traumatic neurodegenerative
sequelae are not understood. Understanding the mechanisms, which render the traumatized
brain susceptible to neurodegeneration, will guide the development of timed and targeted
therapies to prevent the severe neurological decline seen in people at risk.
Recent hypothesis, based on post-mortem observations, attribute the mechanisms underlying
the risk relationship between brain injury and neurodegeneration to disturbed metabolism,
protein aggregation and axonal injury caused by the impact. Our hypothesis is that the
increased susceptibility to neurodegeneration for people with a history of traumatic brain
injury is caused by early injury-induced changes in the reactivity of highly specialized immune
cells in the brain, called microglia. According to our hypothesis, microglia in the traumatized
brain are sensitized to respond more vigorously to a subsequent injurious event. This phe‐
nomenon is named microglia priming [8]. Primed microglia are in a “ready-to-go” state which,
if triggered by a challenge – for example a systemic infection, surgery or vaccination occurring
even later in life –, may outburst in a severe pro-inflammatory event which results in prolonged
delirium and cognitive deficit. The pathways that regulate microglia priming are largely
unknown. Our group has recently demonstrated that activated complement, a part of the
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innate immune system, is one of the triggers to switch the microglial phenotype from resting
to primed, sensitizing the brain for accelerated pathology. It is apparent that knowledge of the
regulatory pathways that control microglia priming will help to identify new therapeutic
targets and guide in the development of novel strategies to treat patients at risk.
In this chapter we review the clinical evidence supporting the increased risk of many athletes
and military personnel to develop a neurodegenerative disease. We report the neuropatho‐
logical changes observed in the post-mortem brain tissue of donors who died of chronic
traumatic encephalopathy, considered today as the disease which best represents the neuro‐
pathology of the concussive brain. We review the inflammatory changes which occur in the
post-mortem brain. We present the current hypothesis of tau pathology and our novel
hypothesis of microglia priming as putative mechanisms underlying the increased suscepti‐
bility of the traumatized brain to early on and accelerated neurodegeneration, and we discuss
how these two hypotheses may co-exist. We focus on the candidate pathways, which may
regulate the transition from the resting to the primed state and those, which may regulate the
transition from the primed to the active state.
Our effort over the past 10 years has been directed to study the role of the complement cascade
in the nervous system [8-14]. To date we have collected evidence which support a role for
complement in microglia priming [8] as well as the protective role of inhibitors of complement
activation in nerve damage [10,13]. Therefore, in this chapter we focus on the complement
system as a potential target for therapy to fight neurodegeneration. We propose our conclu‐
sions and future directions towards which research should invest to identify targets, design
drugs and test therapies to interfere with the changes occurring in the brain after recurrent
trauma and prevent the neurodegenerative sequelae of events which take the life of many
athletes and military forces.
2. Clinical evidence
Over the past decades, clinical studies have shown that traumatic brain injury (TBI) is a risk
factor for the development of neurodegenerative diseases, including Alzheimer’s disease
(AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS), manifesting even
decades after the trauma [15-19]. For example, a retrospective case-control study showed a
link between head trauma with loss of consciousness and AD, with the strongest association
in cases without a history of familial AD and in males [15]. Another study on 196 subjects, who
developed PD, showed that the frequency of head trauma was significantly higher in cases
than controls. Furthermore, the association was higher for men than women [20]. Also in
studies performed on twins, the sibling with the onset of PD at a younger age was more likely
to have sustained a head injury [16]. Another case-control study of 109 ALS cases and 255
matched controls found that multiple head injuries increased the risk of developing ALS by
11 fold [17].
Additional evidence suggests that also mild forms of TBI, including repetitive concussive
injury without loss of consciousness, can trigger chronic neurological problems. The first
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description of traumatic chronic brain damage dates back to 1928 and was termed punch drunk
syndrome, due to its association with boxing. In 1937, Millspaugh renamed this syndrome
dementia pugilistica but only forty-five years later Corsellis et al [21] described the associated
neuropathological changes in a case series of fifteen retired boxers. Their findings included
cerebral atrophy, neurofibrillary tangles and hypopigmentation of the substantia nigra. More
recent studies have shown that such neuropathological changes are not restricted to boxers
but also occur in athletes who practiced other contact-sports such as American football, hockey,
soccer and professional wrestling. In addition, the same neuropathological changes also occur
in victims of physical abuse, in soldiers engaged in military operations and in circus acrobats
repeatedly shot out of a cannon [1,6,22-25]. For example, a study in a case series of postmortem
brains from U.S. military veterans exposed to blast and/or concussive injury, found evidence
of neuropathology similar to that observed in young amateur American football players and
a professional wrestler with histories of concussive injuries [26]. In addition, neuropatholog‐
ically confirmed dementia pugilistica was found in American football players with asympto‐
matic concussions but who played positions, such as lineman, with the greatest exposure to
repeated head blows [27], suggesting that also subconcussive trauma leads to chronic neuro‐
degeneration [28].Therefore the neuropathological changes associated with dementia pugilisti‐
ca are the general outcome for individuals with a history of repeated head trauma.
Over the last decade, the chronic brain damage caused by multiple concussive injuries has
been renamed chronic traumatic encephalopathy (CTE). CTE is defined as a neurodegenera‐
tive disorder, which occurs years or decades after concussive head trauma. In the case of
athletes, it often manifests when the sporting career has already ended [22]. The clinical
symptoms of CTE vary from mild behavioral changes, such as apathy, to severe cognitive
deficits accompanied by movement disorders (e.g. parkinsonism) and neuropsychiatric
problems such as disinhibition, aggressiveness and hypomania, often culminating in violent
behavior [29] and suicidal acts [22-24]. The heterogeneity of the symptoms is likely reflective
of the brain regions affected. Because of the heterogeneity of clinical symptoms of CTE, its
extensive overlap with other causes of dementia and the lack of definite guidelines for a clinical
diagnosis of CTE, it has been difficult to distinguish between CTE, AD, frontotemporal lobar
degeneration (FTLD) or aging, especially in advanced disease. Therefore, the prevalence of
CTE in the demented population has been difficult to establish. Early studies suggest that the
prevalence of CTE in professional boxers is about 20% [30]. More recent MRI studies showed
brain abnormalities, including atrophy, dilated perivascular spaces and diffuse axonal injury,
in 76% of professional boxers [31]. Another recent study in a sample of 513 retired players of
the American National Football League (NFL) Association, indicated possible cognitive
impairment in 35.1% of retirees [32]. A large study completed on 2552 retired players of the
American NFL Association found that retired players with three or more reported concussions
(34.4%) had a threefold prevalence of significant neuropsychiatric problems compared with
retirees without a history of concussion. They also observed an earlier onset of AD in the
retirees than in the general American male population [4]. Overall, these findings suggest a
link between recurrent concussions and increased risk of dementia. However, definite
guidelines for the clinical diagnosis of CTE and future prospective longitudinal studies on
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large populations would probably provide more accurate incidence and prevalence of CTE
over the coming years.
3. Neuropathological changes
Fourty years ago, Corsellis et al. [21] performed the first series of autopsies in professional
boxers with dementia pugilistica and reported neuropathological changes which were con‐
firmed in 2005 by Omalu et al. in the first autopsy from a NFL player [6]. In 2008, the Center
for the Study of Traumatic Encephlopathy (CSTE) at Boston University School of Medicine
established the CSTE brain bank at the Bedford VA Hospital to collect post-mortem brain and
spinal cords of athletes, military veterans and civilians who experienced repetitive concussive
injury. In 2009, McKee et al. at the CSTE performed a retrospective study on the archival
literature and the three new cases available at the brain bank at that time. They verified the
neuropathological findings by Corsellis and Omalu in 49 additional cases of confirmed CTE
[22]. Today the CSTE collected over 100 brains with histories of repetitive mild traumatic brain
injury. Of these, over 60 cases have been fully analyzed and diagnosed with neuropathologi‐
cally confirmed CTE [33]. Overall, the neuropathological findings are consistent and together
make CTE a disorder distinctive from other forms of neurodegeneration.
3.1. Gross pathological changes
Macroscopic examination of the CTE brain shows generalized atrophy of the frontal and
temporal cortices, median temporal lobe, diencephalon and mammillary bodies; thinning of
the corpus callosum and atrophy of the cerebral subcortical white matter; pallor of the
substantia nigra and locus coeruleus. Frequent findings also include cavum septum pelluci‐
dum with fenestrations; dilation of the lateral and third ventricles [22]. These latter changes
are probably caused by the mechanical shearing forces of the traumatic impact, which produce
a fluid wave through the ventricular system.
3.2. Microscopic neuropathological changes
Microscopically, CTE is characterized by abundant neurofibrillary inclusions in the form of
neurofibrillary tangles (NFTs), neuropil threads (NTs) and glial tangles (GTs) [22,34-36].
Tangles are intracellular thread-like aggregates of hyperphosphorylated tau protein[37]. Tau
is an axonal protein whose normal function is to promote microtubule assembly and stability
by binding to microtubules via its microtubule-binding domains conserved in all of its six
isoforms. Hyperphosphorylation of tau at its several threonine or serine phosphorylation sites
makes tau prone to aggregation in the form of tangles, thereby reducing microtubule binding.
This causes disassembly of the microtubules, ultimately resulting in impaired axonal transport
and compromised neuronal function [38].
Like in CTE, also in AD and other tauopathies, tau is found in a hyperphosphorylated form
and tangle aggregates [38]. In addition, the specific tau isoforms found in CTE are indistin‐
guishable from those found in AD [35]. However, tau deposition in CTE is topographically
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and quantitatively distinct from AD. In CTE NFTs deposition is often found in greater densities
compared to severe AD. The distribution of tau NFTs in CTE is irregular and affects primarily
the superficial cortical layers with foci at the depths of the sulci, in the diencephalon, basal
ganglia and brainstem, and surrounding blood vessels [5,22]. By contrast, NFTs in AD are
preferentially distributed in the hippocampus and in large projection neurons in layers III and
V of the cortex [39].
Deposition of β-amyloid (Aβ), a major feature of AD pathology, is only found in 40-45% of
CTE cases [22]. Furthermore, Aβ deposits in CTE are generally found in the form of diffuse
plaques rather than neuritic plaques typically present in the AD brain. Aβ is generated from
amyloid precursor protein (APP) by the action of β- and γ- secretases [40]. APP is highly
expressed by neurons and is thought to promote axonal sprouting, neurite outgrowth and
synaptogenesis, critical for axonal survival after damage [41-44]. However, APP rapidly
accumulates in neurons and axons after injury, especially in truncated axonal bulbs [45]. This
may stimulate overproduction of Aβ and accumulation in the extracellular space in the form
of diffuse plaques [46].
The TAR-DNA-binding protein 43 (TDP-43) is another protein, which aggregates in the
neurodegenerative brain. It was initially considered to be a specific neuropathological feature
of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and ALS
[47] but it is now apparent that TDP-43 accumulation occurs in several other neurodegenera‐
tive diseases including AD [48], dementia with Lewy bodies [49] and CTE [18]. In CTE, TDP-43
immunoreactivity is commonly seen in the frontal and medial temporal cortices, brainstem,
diencephalon, substantia nigra pars compacta, amygdala, hippocampus, caudate, putamen,
thalamus and hypothalamus [1,18].
Accumulation of α-synuclein, the main protein component of the Lewy body aggregates seen
in PD, has not been reported in CTE [22].
Studies in man and animal models have also shown that the complement system is a key
component of the neuropathology of severe TBI [50]. Although studies to verify complement
activation in repetitive mild TBI or in CTE are lacking, the proved neuropathological role of
complement in severe TBI [50] , AD [51,52], prion disease [53], ALS [14,54] and traumatic
peripheral nerve injury [9-13], makes complement a likely player also in the neuropathology
of concussive injuries and CTE. Complement is a key component of innate immunity. Its
activation induces chemotaxis of inflammatory cells, facilitates solubilisation and clearance of
opsonised immune complexes, mediates cell lysis, and influences adaptive immunity [55,56].
Activation occurs via three distinct routes: the classical, the lectin and the alternative pathways.
The classical pathway is activated by the binding of C1q to antigen-antibody complexes or
directly to “danger” epitopes. The lectin pathway is triggered by binding of mannose binding
lectin to certain carbohydrates on the pathogen surface, whereas the alternative pathway starts
by spontaneous low-rate hydrolysis of C3 which binds to activated factor B on a surface lacking
complement inhibitors. Irrespective of the initial recognition pathway, all three routes
converge in the cleavage of C3 and downstream in the assembly of the membrane attack
complex (MAC) a pore through the cell membrane that can result in lysis of the target cell [55,
56]. Because of the tendency of complement to drift from its target site of activation to adjacent
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areas, healthy tissue is equipped with a battery of regulators which keep complement activa‐
tion in check [55,56].
Deposits of the MAC component C9 have been found on injured neurons after TBI [50] and
high levels of fB, C3 and sC5b-9 (soluble MAC) have been detected in the cerebrospinal fluid
(CSF) of patients with severe TBI during the first 10 days after trauma [57]. Mice deficient in
the C3 or C5 components subjected to traumatic brain cryoinjury showed reduced neutrophils
and secondary tissue damage compared to their wildtype littermates [58]. TBI on fB-/-
transgenic mice or mice treated with a monoclonal anti-fB antibody showed reduced post-
traumatic neuronal cell death, a strong upregulation of the anti-apoptotic mediator Bcl-2 and
downregulation of the pro-apoptotic Fas receptor compared to the fB+/+ littermates, implicating
the alternative complement pathway in the progression of the secondary neuronal death
[59,60]. Neurological function after TBI was improved in transgenic mice with brain-targeted
overexpression of complement receptor 1-related protein y (Crry), a potent inhibitor of the C3
convertase [61] or in mice treated with a recombinant Crry molecule (Crry-Ig) in which Crry
is fused to the non-complement fixing mouse IgG1 Fc region [62]. Further, mice treated with
C1 inhibitor, a serine protease inhibitor of the classical and lectin complement pathways,
showed reduced neurobehavioural deficits and contusion volume after controlled cortical
impact brain injury [63]. Involvement of the terminal complement pathway in experimental
TBI has been proven because mice lacking the sole membrane bound regulator of the MAC,
CD59a, display increased neuronal cell death and brain tissue destruction compared to CD59a
+/+ littermates [64]. Our group has initially shown that MAC is a key component of axonal injury,
driving Wallerian degeneration after peripheral nerve trauma, and we have also recently
proven that exogenous blockers of MAC assembly are neuroprotective in an experimental
mouse model of severe closed head injury (unpublished observations).
4. The tau hypothesis
Neuropathological evidence suggest that CTE begins focally at the cortical sulci and perivasc‐
ularly, spreading slowly over decades to involve the cortex, medial temporal lobe, diencepha‐
lon, basal ganglia, brainstem and spinal cord [33]. A recent post-mortem study on 85 donors
of the CSTE brain bank classified CTE into four stages based on topographically predictable
pattern of tau pathology. Stage I is characterized by perivascular NFTs, and is clinically
associated with attention and concentration disturbances. Stage II is characterized by NFTs in
superficial cortical layers, in the nucleus basalis of Meynert and locus coeruleus, and is
clinically associated with depression, mood swings and short-term memory loss. Stage III is
characterized by cerebral atrophy, enlargement of the ventricles and pallor of the substantia
nigra. In addition, tau pathology is widespread in the cortex, diencephalon, brainstem and
spinal cord. Stage III is clinically associated with memory impairment, executive dysfunction
(e.g. problems with planning, organizing, multi-tasking, judgment), depression and irritabil‐
ity. Stage IV is characterized by further brain atrophy, ventricular dilation, pallor of the
substantia nigra and locus coeruleus. Tau pathology is widespread also to white matter regions
and is accompanied by neuronal loss, gliosis of the cerebral cortex and hippocampal sclerosis.
Traumatic Brain Injury84
Clinically, stage IV presents with severe cognitive problems, memory loss, executive dysfunc‐
tion, depression, irritability and increased violence [33].
According to the current hypothesis on the initiation and propagation of CTE pathology, the
initial brain changes are caused by acceleration and deceleration forces provoked by the
traumatic injury which stretch and disrupt neuronal and axonal membranes [65]. These acute
cellular changes trigger a cascade of neurochemical dysfunctions, including a deregulated
influx of calcium ions and efflux of potassium ions, which depolarize the axonal cell mem‐
brane. Depolarization in turn results in the release of excitatory neurotransmitters, including
glutamate, which binds to its receptors to fire more action potentials, mediating the influx of
more calcium ions. These events trigger an excitotoxic cascade, which depletes energy stores,
impairs oxidative metabolism and results in the release of calpains, calcium-dependent
proteases, which cause further tissue injury [66,67]. Mechanical shearing forces can also cause
disruption of axons and dissolution of microtubules, impairing axonal transport and causing
initial swelling followed by axotomy and in the end by Wallerian degeneration [66,67]. These
changes are typically located in the cortical sulci, which is where tau pathology begins.
The initial trigger of tau phosphorylation, misfolding, truncation and aggregation into NFTs
may be induced by caspases and calpains, released by the stretching of axons at the moment
of the traumatic impact. Dissolution of microtubules, as a result of axonal injury, will also
release tau, which is then phosphorylated and polymerizes into toxic filaments. The toxic gain
of function of tau protein is supported by studies in which human tau overexpressed in
lamprey central neurons becomes phosphorylated, accumulate in filamentous deposits and
causes microtubule and synapse loss [68,69].
A recent hypothesis suggests that the predictable spreading of tau pathology from stage I to
stage IV may be due to transfer of toxic tau species between neurons [70-73]. This can occur
via a prion-like propagation of misprocessed tau (reviewed in [74]) and/or via the internali‐
zation of small misfolded tau species by bulk endocytosis at the somatodendritic compartment
or at the axon terminals. Once exogenous tau is taken up by the neuron, it can be transported
anterogradely and retrogradely, accumulating and enhancing tauopathy [75]. In addition to
the trans-synaptical transfer of tau, paravenous drainage pathways may also regulate the
extracellular levels of tau, Aβ and TDP-43. For example, a recent study using two-photon
imaging of small fluorescent tracers showed that the CSF enters the brain parenchyma along
paravascular spaces that surround penetrating arteries and that the brain interstitial fluid is
cleared along these paravenous drainage pathways. In addition, fluorescent-tagged Aβ was
transported along this route whereas impairment of the paravascular pathway suppressed
clearance of soluble Aβ [76,77]. These findings suggest that impairment of the paravenous flow
by the trauma may contribute to the accumulation of soluble proteins in neurodegenerative
diseases. For example, APP may be inefficiently cleared by paravascular pathways and
aberrantly cleaved to form Aβ. To date, the role of Aβ in the pathogenesis of CTE is unclear.
On the other hand, there is evidence that accumulation of TDP-43 in CTE may be neurotoxic.
Recent in vivo and in vitro studies suggested that overexpression of human TDP-43 and its
relocation from the neuron nuclear compartment to the cytoplasm are associated with
neurodegeneration and cell death [78-80].




In brain donors and experimental animal models, TBI has been associated with increased
reactivity of microglia [81,82]. Microglia are the resident macrophages of the brain. Similar to
their peripheral equivalent, they are able of phagocytosis, antigen presentation and secretion
of inflammatory mediators [83]. They continuously survey the local environment to detect and
alert neighbouring cells of non-physiological changes but, despite their very dynamic pheno‐
type, microglia are constantly suppressed in the normal brain [84]. In rodents, primates and
humans, microglial hyper-reactivity persists for months to years after TBI, indicative of chronic
neuroinflammation [85-89]. This phenotype is remarkably similar to the chronic microglial
reactive state of the AD [90] or ageing brain [91].
6. The microglia priming hypothesis
The hypothesis of microglia priming proposes that in the ageing or neurodegenerating brain,
microglial cells are chronically sensitized to respond more vigorously to a subsequent injurious
event (reviewed in [92,93]). This is profoundly discordant with the behavior of peripheral
macrophages, despite their common monocytic lineage origin with microglia. In fact, in the
periphery, an initial challenge (e.g. lipopolysaccharide, LPS) conditions macrophages to
produce a suppressed response upon restimulation with a second challenge [94].
The notion of microglia priming was initially proposed by Perry in 2007 [95] and later by van
Gool [96] based on clinical observations, which reported a deleterious effect of systemic
infections on the clinical outcome of elderly people or individuals with neurodegenerative
diseases. For example, when elderly patients become delirious during infections, treatment of
the infection may go well but the patients emerge with dementia. Similar observations have
been made after postoperative delirium in elderly hip fracture patients free from preexisting
dementia [97,98]. Other studies have shown that new episodes of cognitive decline in AD cases
were concomitant to systemic inflammatory events [99,100]. Systemic infections have also been
linked to worse outcome in multiple sclerosis patients [101]. Likewise, lung inflammation is
associated with worse neurological outcome in patients with severe brain trauma [102].
According to the priming model, microglia are the cells responsible for the increased suscept‐
ibility of the brain to peripheral events.
In prion disease models, microglial priming is evident even in the preclinical stage and LPS
challenge exacerbates neuronal death, induces acute cognitive impairment and accelerates
disease progression [103-105]. In AD models, repeated LPS challenges exacerbate tau pathol‐
ogy [106], amyloid deposition [107] and inflammation [108]. In the superoxide dismutase
(SOD) mouse model of familial ALS, chronic LPS administration exaggerates motor neuron
degeneration, precipitates disease progression and elevates production of pro-inflammatory
cytokines [109]. In animal models of mild TBI, sepsis worsen post-traumatic mortality and
weight loss, motor deficit and cognitive impairments, and further exacerbates neuronal cell
death concomitant with over-activation of microglial cells in the peri-lesional area [110]. These
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studies all suggest that microglia priming places subjects at risk for exacerbated neuropathol‐
ogy from an early stage of disease.
Despite the likelihood that microglia priming is an important event in neurodegeneration, its
triggers are just starting to be uncovered.
6.1. Transition from resting to primed state
In the normal brain, microglia are dynamic but suppressed by the concerted action of regula‐
tory proteins [84]. We propose that in the aged or traumatized or neurodegenerating brain,
microglia become primed due to the abrogation of this suppression or due to the stimulation
by pathological proteins.
Suppressing mechanisms include the interaction between neuronally derived proteins such as
the glycoprotein CD200 or fractalkine, and their receptors on microglial cells. For example,
deletion of CD200 in mice, results in exacerbated microglial activation in several models of
inflammation [111,112] whereas enhancing CD200 signaling, by intracerebral injection of the
CD200 fusion protein, rescues the overactivated microglial phenotype in aged mice challenged
with LPS [113]. In vitro, treatment of fractalkine ligand, CX3CL, to LPS-stimulated microglia
attenuates production of inflammatory mediators including IL-1β, IL-6, TNF-α and inducible
nitric oxide synthase (iNOS) [114-116]. In vivo, fractalkine receptor deficient mice challenged
with LPS show amplified microglial expression of IL-1β and prolonged depressive-like
behavior compared to wildtype or heterozygote mice [117] whereas inhibition of IL-1β
associated inflammatory enzymes blocked the depressive behavior and restored microglia
homeostasis [118]. More recent studies proposed that the brain specific microRNA-124
(miR-124) is a potential suppressor of microglial function [119]. Overexpression of miR-124 in
bone marrow-derived macrophages resulted in lower levels of TNF-α and iNOS, and a higher
level of the anti-inflammatory cytokine TGF-β1, reflecting a quiescent phenotype. On the other
hand, knock down of miR-124 attenuated the downregulation of MHC class II and CD45 in
microglia and macrophages, again pointing towards a role for miR-124 in maintaining the
quiescent phenotype. Ponomarev et. al. [119] proposed that the inhibiting activity of miR-124
on microglial function is mediated via C/EBP-α and its downstream effector PU.1. Both
transcription factors are involved in differentiation of myeloid and monocytic lineage cells and
are downregulated in miR-124 transfected cells.
Microglia priming may also be induced by stimulation with pathological proteins, including
protein aggregates such as Aβ and NFTs formed after TBI. For example, in vitro studies have
shown that exposure to Aβ primes microglia to produce an exaggerated respiratory burst
during phagocytosis [120]. In addition, our group has recently shown that deposition of
activated complement proteins, known to opsonize damaged axons after trauma [9,11], can
also regulate the microglial phenotype [8,121]. In mice, deletion of the major regulator of the
C3 convertase, Crry, induces deposition of active C3 in tissue and induces microglia priming,
likely by binding to complement receptor 3 (CD11b/CD14) on microglia. Crry deficient mice
– with primed microglia – showed exaggerated microglia expression of pro-inflammatory
molecules following LPS challenge. Furthermore, we identified evidence of microglia priming
in the normal appearing white matter of brain donors with progressive multiple sclerosis and
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showed that, in an experimental model of multiple sclerosis, microglia priming is responsible
for earlier disease onset and more severe clinical course compared to unprimed mice [8,121].
After recurrent mild TBI, deposition of active complement proteins, including C3, may occur
in response to diffuse axonal injury, provoked by accelerating and decelerating forces.
Disrupted axonal membranes expose epitopes, which are recognized as “danger” and are
targeted by complement proteins. C3 activation products may then bind to CR3 on microglia
and induce priming. Other sensors of endogenous tissue damage are toll-like receptors (TLRs)
which, in concert with complement proteins [122], recognize as “danger” conserved molecular
patterns, whether it is exogenous pathogens or endogenous tissue damage that are detected
[123]. TLR2 and 4 are expressed by microglia [124,125] and have been shown to drive inflam‐
mation in response to the alarmin high mobility group box-1 protein (HMGB1) [126], a danger-
associated molecular pattern (DAMP) molecule which is released by injured cells in a C3-
dependent manner [127] within 30 minutes to 6 hours after severe trauma [128]. Although the
TLR signaling is predicted to initiate an acute pro-inflammatory response [129], ligation of
TLRs may be involved in priming of microglia or in mild (recurrent) trauma.
6.2. Transition from primed to active state
Exposure of primed microglia to an injurious stimulus – i.e. infections, surgery or vaccination
– can lead to microglia overactivation, which trigger or accelerate dementia.
Peripheral infections are a widely recognized trigger of cognitive decline and delirium in
elderly and AD patients. For example, AD patients who experienced systemic infections,
showed concomitant precipitating cognitive decline. The periods of infection were associated
with elevated levels of TNF-α. Notably, subjects with low TNF-α levels did not show cognitive
decline over the 6-month investigated period [100]. Another study showed that cognitive
impairment in AD patients was concomitant to a systemic inflammatory event and was
preceded by raised levels of IL-1β [99]. Surgery can also activate the peripheral immune system
and trigger an exaggerated inflammatory response in the brain [130]. Postoperative cognitive
dysfunction (POCD) is the decline of cognitive performance observed after surgery, with
possible long-term effects, such as changes in personality and social integration [131]. POCD
has an estimated prevalence of 15-25% in patients over the age of 60, with age as main risk
factor [130]. In experimental surgery, aged mice produce significantly higher levels of IL-1β
compared to wildtype mice, supporting a role for surgery as a trigger for activation on a brain
primed by aging [130]. Vaccination may also be a potential trigger for the transition from
primed to active microglial state [132]. This would be especially relevant in view of research
into developing vaccinations for AD [133-135]. Drug addictions, such as those reported for
some cases of CTE who died from drug overdose, can also regulate the activation of microglia.
For example in mice, microglial activation is an early step in methamphetamine-induced
neurotoxicity[136]. The use of steroids could also regulate microglial function, but to our
knowledge there are no studies which have tested this hypothesis.
An essential question is how the communication between the periphery and the brain occurs.
It is well known that peripheral inflammation can activate CNS centers by a number of routes,
including the circumventricular organs, vagal afferents, and the brain endothelium (see [137]
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for review). Blood-borne cytokines are thought to diffuse into the brain through fenestrated
capillaries and stimulate parenchymal astrocytes to release secondary mediators within the
brain such nitric oxide and prostaglandins [138]. Circulating cytokines could also induce the
production of pro-inflammatory cytokine by macrophage-like cells in the circumventricular
organs and choroid plexus, acting directly or indirectly on neurons which project to the brain
parenchyma [139]. Another route of transmission of the peripheral immune message to the
brain is via neural afferent pathways. This has been functionally demonstrated by vagal nerve
resection experiments that abrogated LPS-induced inflammation and sickness behavior in
rodents [140,141]. TLRs, expressed by many immune cells and also by endothelial cells [142],
are the obvious responders to systemic infections especially to LPS via the TLR4 and its co-
receptors MD2 and CD14 [143]. Therefore they are likely involved in mediating inflammation
from the periphery to the brain. For a comprehensive review on TLR signaling see [144].
Overactivation of microglia can ultimately precipitate neuropathology and the clinical
outcome of elderly or patients with ongoing neurodegeneration [99,100,145-147]. For example,
microglial pro-inflammatory cytokines can stimulate γ-secretase activity and enhance APP
levels and amyloidogenic APP processing, potentially exacerbating Aβ pathology [146,147].
Another example comes from studies on the triple transgenic mouse model of AD in which
overexpression of IL-1β increases tau phosphorylation [145]. The hypothesis of microglia
priming in recurrent mild brain trauma is shown in Figure 1.
7. Therapeutical targets
Currently there is no treatment or therapy to stop or reverse the neurodegenerative sequelae
triggered by repetitive concussions or CTE. It is apparent that knowledge of the regulatory
pathways that control tau or Aβ pathology, as well as the mechanisms that regulate microglia
priming will help to identify new therapeutic targets and guide in the development of novel
strategies to treat patients at risk. Therapies could be timed and targeted to intervene early
after brain trauma to prevent accumulation of protein aggregates and priming of microglia,
for example by administering therapies as prophylactic cover before a sporting match or a
military operation. Alternatively, therapies could be targeted to reduce the impact of periph‐
eral insults on primed cells, by monitoring traumatized patients for years post-trauma and
administering therapies as prompt interventions for example during systemic infections.
Since the initiating events of CTE include accumulation of hyperphosphorylated tau and in
some cases of Aβ, targeting the formation or processing of these protein aggregates would
seem to be a promising strategy for treatment. However, AD research is still controversial on
the pathological role of tau and APP/Aβ metabolism. Specifically, it is still unclear whether it
triggers chronic neurodegeneration or it is simply the epiphenomenon of underlying patho‐
genic responses to neuronal damage. Over the past decade, our group has collected evidence
which support a protective role for complement inhibitors in axonal damage [8-10,13]. We
demonstrated that both genetic and pharmacological inhibition of MAC formation protects
the peripheral nerve from early axon loss after traumatic injury [9,10,148], and stimulates post-
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traumatic axonal regeneration and functional recovery [149]. In addition, blockade of C3
activation in a mouse model of microglia priming reversed priming and suppressed experi‐
mental autoimmune encephalitis (EAE)-induced inflammation [8]. Studies from other groups
have also shown that inhibition of C3 activation via the alternative pathway is protective in
the experimental mouse model of closed head injury [60,62]. The complement system plays a
vital role because it is the first line of defence against pathogens; it generates chemoattractants
for inflammatory cells, facilitates solubilisation and clearance of opsonised immune com‐
plexes, mediates cell lysis, and influences adaptive immunity [150,151]. Therefore, the stage at
which the complement system should be inhibited to block its detrimental effects but maintain
its protective functions, is of considerable importance. The problem of systemic inhibition of
complement might be overcome by targeting the agent to a specific site or choosing an agent,
which allows certain physiological functions of complement while inhibiting others. For
Figure 1. Hypothesis of microglia priming in recurrent mild brain trauma. In the normal situation, a peripheral event,
such as an infection, is the first hit to the brain, activating resting microglia to produce inflammatory mediators affect‐
ing neuronal function and producing sickness behavior or delirium. In the context of recurrent mild brain injury, mild
TBI provokes mechanical accelerating and decelerating forces, which cause axonal stretching and damage fragile ax‐
ons, producing diffuse axonal injury. Diffuse axonal injury is characterized by disrupted axonal transport and microtu‐
bule disassembly, which culminate in the accumulation of tau and APP deposits, forming in some cases Aβ plaques
around damaged axons. Impaired axonal transport also results in the formation of axonal swelling and axotomy, trig‐
gering Wallerian degeneration. Degenerating axons activate complement, which accumulates on targeted damaged
membranes. MAC amplifies tissue injury whereas activated C3 products, C3b/iC3b, bind to their receptor CR3 on mi‐
croglia. These injury-provoked cellular and neurochemical changes are the first hit which initiates diffuse axonal path‐
ology and triggers priming of microglia for over-activation in response to a second hit. Under these circumstances, a
peripheral injurious event, such a subsequent brain trauma, an infection, surgery, vaccination, use of recreational
drugs or steroids, is the second hit to the brain that over-activates primed microglia to produce an elevated amount of
inflammatory mediators. Pro-inflammatory molecules facilitate spreading of tau and Aβ pathology, driving neuropa‐
thology, accelerating cognitive decline and ultimately determining dementia.
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example, specific blockers of the CR3 receptors on microglia could be useful in modulating
microglia priming whereas targeting the terminal complement pathway could be an attractive
proposition because it maintains function of the initial steps of the complement cascade,
including opsonisation, but it blocks the detrimental effect of the MAC on neuronal mem‐
branes. The therapeutic effects of complement inhibitors remain to be tested in experimental
models of CTE but it is of high relevance since the recent advent of complement drugs into the
clinic makes complement therapy a real option for patients.
Ultimately, prevention is the logical option. To this end, the World Medical Association
(WMA) has recommended guidelines to make sport safer. For example, changing the boxing
rules to reduce the number of fighting rounds and to introduce the mandatory use of thickly-
padded head gear and gloves to diminish the impact from a punch may lower the risk of CTE
in boxers (WMA, 2005). However, in sports where repeated blows to the head are unavoidable,
appropriate assessment and management of the concussive injury may be critical for prevent‐
ing long-term consequences. Therefore, a number of recommendations were developed
following the 1st (Vienna 2001), 2nd (Prague 2004), 3rd (Zurich 2008) and 4th (Zurich 2012)
international consensus conference on concussion in sport [152]. These include removal of an
injured athlete from the field and strict monitoring over the first few hours following concus‐
sion, whereas returning to the field should follow a stepwise protocol from no activity to light
aerobic exercise to full practice and playing.
8. Conclusions and future directions
Although public awareness and media attention on the long-term effects of repetitive brain
trauma - especially in professional athletes - have increased in recent years, knowledge of the
neurobiology and pathogenesis of this condition is still limited and treatment is not available.
However, as the number of professional athletes increases and sports get more competitive,
the expectation is that the number of sports-related CTE cases may increase in the future. This
prediction together with the potential of CTE to impact a broad population from athletes to
veterans to victims of abuse, make CTE an important public health issue. Therefore research
should invest in this area. It is clear that accurate clinical diagnostic criteria for CTE alone or
mixed disease and prospective longitudinal studies, terminating in autopsy, would be
essential to identify patients, develop biomarkers, further our knowledge on the temporal
evolution and mechanisms of the disease. It would be also important to determine whether
severity of the trauma, number of exposures, age at first exposure, gender, age and race may
play a role in the development of CTE.
Functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (voxel-based
morphometry) seem a promising tool to monitor brain damage [153]. For example, studies
carried out at baseline and repeated immediately after concussion and later until symptom
resolution, have shown that fMRI is sensitive enough to detect abnormal activation patterns
in varsity hockey and football athletes who have suffered a concussion. Therefore, fMRI could
provide an objective way to measure the severity of a concussion and subsequent recovery
[153].
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In the future, it would also be important to learn from advances made in other fields of
neurodegeneration research, based on the consideration that CTE and other neurodegenera‐
tive disorders share many neuropathological and neurocognitive traits. For example, CTE
patients could be screened for genes associated with AD, or FTLD or ALS. Epidemiological
data have already implicated the apolipoprotein E epsilon 4 (APOE ε4) allele, important
genetic risk factor for AD, in the development of AD after TBI [154,155] and carriers of the
APOE ε4 allele were found to be at increased risk of Aβ accumulation following brain injury
[156]. However, large epidemiological studies on the influence of the APOE ε4 allele on the
risk of CTE are still missing. Other candidate genes which may turn out to be risk factors for
CTE, and therefore predict poor outcome after trauma, may include TARDBP, encoding for
TDP-43 involved in FTLD and ALS [157]; the GRN gene, encoding granulin and associated
with FTLD [158]; the MAPT gene, encoding for tau and mutated in some cases of FTLD [158].
In addition, the future development of experimental animal models which best mimic the
neuropathology seen in man after repeated mild brain injury or CTE, would be crucial to
identify the mechanisms of trauma-induced neurodegeneration and test neuroprotective
therapies. Currently available animal models of CTE involve the triple transgenic AD mouse
because it develops hyperphosphorylated tau and Aβ plaques. However it lacks the wide‐
spread neuronal loss which is observed in the human disease [159,160], making experimental
observation difficult to translate into the clinic. A recently published transgenic rat model of
AD, line TgF344-AD, may represent a better model to study CTE in rodents [161]. This
transgenic rat expresses mutant human APP and presenilin-1, each independently associated
with early onset familial AD. This AD model expresses all hallmarks of human AD, including
Aβ plaques, hyperphosphorylated tau, gliosis and loss of cortical and hippocampal neurons,
including age-dependent cognitive deficit [161]. Therefore, these rats may be a good model to
monitor Aβ and tau pathology as well as neuronal loss and cognitive impairment after
repetitive mild TBI, and also test therapies to stop or reverse post-traumatic neurological
deficit. Insights into the mechanisms and treatment options for repeated mild brain injury or
CTE, will assist policy makers (e.g. sports league officials or military commanders) to draw
accurate guidelines for the prevention and the treatment of brain trauma whether in the
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